Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableLeukemiaLymphomaMultiple MyelomaMDSMyelodysplastic/Myeloproliferative Diseases
Interventions
DRUG

Ganciclovir

Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks

Trial Locations (1)

91010

City of Hope National Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00530218 - Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | Biotech Hunter | Biotech Hunter